Bio-Rad Laboratories, Inc. Stock NYSE
Stocks
BIO.B
US0905721082
Medical Equipment, Supplies & Distribution
|
Market Closed -
NYSE
16:10:00 2026-08-20 EDT
|
5-day change | 1st Jan Change | ||
| 365.08 USD | +8.33% |
|
-.--% | +17.50% |
| Market Cap | 9.73B 8.69B 8.1B 7.35B 13.83B 924B 13.93B 97.08B 38B 480B 36.55B 35.75B 1,542B | P/E 2026 * |
43.7x | P/E 2027 * | 42.7x |
|---|---|---|---|---|---|
| Enterprise Value | 8.98B 8.02B 7.48B 6.78B 12.76B 853B 12.86B 89.6B 35.08B 443B 33.74B 33B 1,423B | EV / Sales 2026 * |
3.5x | EV / Sales 2027 * | 3.34x |
| Free-Float |
60.17% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| BIO.B | Delayed | |
Deutsche Boerse AG
| BUW | Delayed |
Last Transcript: Bio-Rad Laboratories, Inc.
| 1 day | +8.33% | ||
| 3 months | +18.01% | ||
| 6 months | +31.80% | ||
| Current year | +17.50% |
| Current year | 244.54 |  | 365.08 |
| 1 year | 244.54 | | 365.08 |
| 3 years | 0 | | 365.08 |
| 5 years | 0 | | 784.4 |
| 10 years | 0 | | 818.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CEO | Chief Executive Officer | 76 | 2002-12-31 |
| President | 61 | 2024-09-08 | |
Roop Lakkaraju
DFI | Director of Finance/CFO | 55 | 2024-04-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CHM | Chairman | 76 | 2011-12-31 |
Jeffrey Edwards
BRD | Director/Board Member | 73 | 2017-04-24 |
Gregory Hinckley
BRD | Director/Board Member | 79 | 2017-04-24 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +8.33% | -.--% | - | - | 9.73B | |
| +0.78% | +4.53% | -21.90% | +12.92% | 178B | |
| +1.17% | +6.80% | -2.69% | +29.25% | 119B | |
| -0.02% | +1.56% | -22.57% | +9.57% | 108B | |
| +2.53% | +2.28% | -44.89% | -9.43% | 75.27B | |
| +1.55% | +4.34% | +4.14% | +74.68% | 62.99B | |
| +0.34% | +1.05% | +19.75% | +67.00% | 53.46B | |
| -0.80% | +3.92% | +0.38% | -27.57% | 51.04B | |
| -0.69% | +0.95% | -17.84% | +22.09% | 40.99B | |
| -1.00% | +2.00% | +30.46% | +11.64% | 32.1B | |
| Average | +0.96% | +2.53% | -6.13% | +21.13% | 80.08B | |
| Weighted average by Cap. | +0.27% | +3.15% | -11.73% | +19.78% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.57B 2.3B 2.14B 1.94B 3.65B 244B 3.68B 25.63B 10.03B 127B 9.65B 9.44B 407B | 2.62B 2.34B 2.18B 1.98B 3.73B 249B 3.76B 26.17B 10.25B 130B 9.86B 9.64B 416B |
| Net income | 225M 201M 187M 170M 319M 21.34B 322M 2.24B 878M 11.1B 844M 826M 35.62B | 230M 205M 191M 173M 326M 21.81B 329M 2.29B 897M 11.34B 863M 844M 36.39B |
| Net Debt | -749M -669M -624M -565M -1.06B -71.1B -1.07B -7.47B -2.92B -36.98B -2.81B -2.75B -119B | -965M -862M -804M -729M -1.37B -91.64B -1.38B -9.63B -3.77B -47.66B -3.63B -3.55B -153B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-13 | US$0.000000 | - | 41 |
| 26-10-12 | US$0.000000 | - | 4 |
| 26-10-09 | US$0.000000 | - | 8 |
| 26-10-08 | US$0.000000 | - | 11 |
| 26-10-07 | US$0.000000 | - | 13 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIO Stock
- BIO.B Stock
Select your edition
All financial news and data tailored to specific country editions
